Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors

GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. The survivors' median follow-up time was 1081 days. Patients were categorized into 5 groups: cord blood (CB; n = 1915), matched related donor (n = 1772), 1-antigen mismatched related donor (1-MMRD; n = 225), matched unrelated donor (MUD; n = 1742), and 1-allele mismatched unrelated donor (1-MMUD; n = 963). In multivariate analysis, ATG decreased overall survival (hazard ratio [HR], 1.403; P = .054) and GVHD-free/relapse-free survival (GRFS) (HR, 1.458; P = .053) in association with increased nonrelapse mortality (NRM) (HR, 1.608; P =03) with CB, whereas it improved GRFS (HR, 0.515; P < .01) and decreased grades II to IV aGVHD (HR, 0.576; P < .01), extensive cGVHD (HR, 0.460; P = .02), and NRM (HR, 0.545; P = .03) with 1-MMUD. ATG did not impact survival with 1-MMRD and MUD. The use of ATG in conditioning is beneficial due to the reduction in acute/chronic GVHD without increasing NRM or disease relapse only in 1-MMUD transplantation. On the other hand, ATG is not recommended for CB transplantation.

Original languageEnglish
Pages (from-to)105-115
Number of pages11
JournalBlood advances
Volume3
Issue number2
DOIs
Publication statusPublished - Jan 22 2019

Fingerprint

Antilymphocyte Serum
Leukemia
Tissue Donors
Unrelated Donors
Survival
Graft vs Host Disease
Recurrence
Mortality
Transplantation
thymoglobulin
Hematopoietic Stem Cell Transplantation
Fetal Blood
Survivors
Japan
Multivariate Analysis
Alleles
Antigens

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. / GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation.

In: Blood advances, Vol. 3, No. 2, 22.01.2019, p. 105-115.

Research output: Contribution to journalArticle

GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. / Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. In: Blood advances. 2019 ; Vol. 3, No. 2. pp. 105-115.
@article{b2ed6771416346a28494aa13ce157d5b,
title = "Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors",
abstract = "Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. The survivors' median follow-up time was 1081 days. Patients were categorized into 5 groups: cord blood (CB; n = 1915), matched related donor (n = 1772), 1-antigen mismatched related donor (1-MMRD; n = 225), matched unrelated donor (MUD; n = 1742), and 1-allele mismatched unrelated donor (1-MMUD; n = 963). In multivariate analysis, ATG decreased overall survival (hazard ratio [HR], 1.403; P = .054) and GVHD-free/relapse-free survival (GRFS) (HR, 1.458; P = .053) in association with increased nonrelapse mortality (NRM) (HR, 1.608; P =03) with CB, whereas it improved GRFS (HR, 0.515; P < .01) and decreased grades II to IV aGVHD (HR, 0.576; P < .01), extensive cGVHD (HR, 0.460; P = .02), and NRM (HR, 0.545; P = .03) with 1-MMUD. ATG did not impact survival with 1-MMRD and MUD. The use of ATG in conditioning is beneficial due to the reduction in acute/chronic GVHD without increasing NRM or disease relapse only in 1-MMUD transplantation. On the other hand, ATG is not recommended for CB transplantation.",
author = "{GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation} and Manabu Wakamatsu and Seitaro Terakura and Kazuteru Ohashi and Takahiro Fukuda and Yukiyasu Ozawa and Heiwa Kanamori and Masashi Sawa and Naoyuki Uchida and Shuichi Ota and Akiko Matsushita and Yoshinobu Kanda and Hirohisa Nakamae and Tatsuo Ichinohe and Koji Kato and Koji Kato and Yoshiko Atsuta and Takanori Teshima",
year = "2019",
month = "1",
day = "22",
doi = "10.1182/bloodadvances.2018025643",
language = "English",
volume = "3",
pages = "105--115",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors

AU - GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation

AU - Wakamatsu, Manabu

AU - Terakura, Seitaro

AU - Ohashi, Kazuteru

AU - Fukuda, Takahiro

AU - Ozawa, Yukiyasu

AU - Kanamori, Heiwa

AU - Sawa, Masashi

AU - Uchida, Naoyuki

AU - Ota, Shuichi

AU - Matsushita, Akiko

AU - Kanda, Yoshinobu

AU - Nakamae, Hirohisa

AU - Ichinohe, Tatsuo

AU - Kato, Koji

AU - Kato, Koji

AU - Atsuta, Yoshiko

AU - Teshima, Takanori

PY - 2019/1/22

Y1 - 2019/1/22

N2 - Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. The survivors' median follow-up time was 1081 days. Patients were categorized into 5 groups: cord blood (CB; n = 1915), matched related donor (n = 1772), 1-antigen mismatched related donor (1-MMRD; n = 225), matched unrelated donor (MUD; n = 1742), and 1-allele mismatched unrelated donor (1-MMUD; n = 963). In multivariate analysis, ATG decreased overall survival (hazard ratio [HR], 1.403; P = .054) and GVHD-free/relapse-free survival (GRFS) (HR, 1.458; P = .053) in association with increased nonrelapse mortality (NRM) (HR, 1.608; P =03) with CB, whereas it improved GRFS (HR, 0.515; P < .01) and decreased grades II to IV aGVHD (HR, 0.576; P < .01), extensive cGVHD (HR, 0.460; P = .02), and NRM (HR, 0.545; P = .03) with 1-MMUD. ATG did not impact survival with 1-MMRD and MUD. The use of ATG in conditioning is beneficial due to the reduction in acute/chronic GVHD without increasing NRM or disease relapse only in 1-MMUD transplantation. On the other hand, ATG is not recommended for CB transplantation.

AB - Antithymocyte globulin (ATG) is widely used to reduce acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD). To clarify the different impacts of ATG for conditioning across different donor types, we retrospectively analyzed patients with acute leukemia (n = 6617) who underwent hematopoietic stem cell transplantation between 2008 and 2015 with ATG (n = 279) or without ATG (n = 6338). Because thymoglobulin is the only ATG drug approved for GVHD prophylaxis in Japan since September 2008, we included thymoglobulin alone in the present analysis. The survivors' median follow-up time was 1081 days. Patients were categorized into 5 groups: cord blood (CB; n = 1915), matched related donor (n = 1772), 1-antigen mismatched related donor (1-MMRD; n = 225), matched unrelated donor (MUD; n = 1742), and 1-allele mismatched unrelated donor (1-MMUD; n = 963). In multivariate analysis, ATG decreased overall survival (hazard ratio [HR], 1.403; P = .054) and GVHD-free/relapse-free survival (GRFS) (HR, 1.458; P = .053) in association with increased nonrelapse mortality (NRM) (HR, 1.608; P =03) with CB, whereas it improved GRFS (HR, 0.515; P < .01) and decreased grades II to IV aGVHD (HR, 0.576; P < .01), extensive cGVHD (HR, 0.460; P = .02), and NRM (HR, 0.545; P = .03) with 1-MMUD. ATG did not impact survival with 1-MMRD and MUD. The use of ATG in conditioning is beneficial due to the reduction in acute/chronic GVHD without increasing NRM or disease relapse only in 1-MMUD transplantation. On the other hand, ATG is not recommended for CB transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85059794915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059794915&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2018025643

DO - 10.1182/bloodadvances.2018025643

M3 - Article

C2 - 30626574

AN - SCOPUS:85059794915

VL - 3

SP - 105

EP - 115

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 2

ER -